share_log

BioVie | 10-Q: Q1 2025 Earnings Report

BioVie | 10-Q: Q1 2025 Earnings Report

BioVie | 10-Q：2025財年一季報
美股SEC公告 ·  2024/11/14 05:52

Moomoo AI 已提取核心訊息

BioVie reported a net loss of $4.2 million for Q1 FY2025 ended September 30, 2024, significantly lower than the $10.7 million loss in the same period last year. Research and development expenses decreased by $6.9 million to $2.0 million, primarily due to the completion of clinical trials in the prior fiscal year. The company had cash and cash equivalents of $20.0 million as of quarter-end.The company is advancing its neurodegenerative disease program with bezisterim (NE3107), having completed Phase 2 studies for Parkinson's disease and designed a new Phase 2 study as potential first-line therapy. Additionally, BioVie received a $13.1 million Department of Defense grant to evaluate bezisterim for long COVID treatment, with trials expected to commence by early 2025.For its liver disease program BIV201, BioVie is finalizing Phase 3 study protocols for treating ascites due to chronic liver cirrhosis after receiving FDA guidance. The company strengthened its financial position through multiple offerings, raising approximately $15.9 million in gross proceeds in October 2024 through registered direct offerings of common stock and warrants.
BioVie reported a net loss of $4.2 million for Q1 FY2025 ended September 30, 2024, significantly lower than the $10.7 million loss in the same period last year. Research and development expenses decreased by $6.9 million to $2.0 million, primarily due to the completion of clinical trials in the prior fiscal year. The company had cash and cash equivalents of $20.0 million as of quarter-end.The company is advancing its neurodegenerative disease program with bezisterim (NE3107), having completed Phase 2 studies for Parkinson's disease and designed a new Phase 2 study as potential first-line therapy. Additionally, BioVie received a $13.1 million Department of Defense grant to evaluate bezisterim for long COVID treatment, with trials expected to commence by early 2025.For its liver disease program BIV201, BioVie is finalizing Phase 3 study protocols for treating ascites due to chronic liver cirrhosis after receiving FDA guidance. The company strengthened its financial position through multiple offerings, raising approximately $15.9 million in gross proceeds in October 2024 through registered direct offerings of common stock and warrants.
BioVie報告截至2024年9月30日的2025財年第一季度淨虧損420萬美金，顯著低於去年同期的1070萬美金虧損。研發費用減少了690萬美金，降至200萬美金，主要是由於在前一個財年完成了臨牀試驗。公司在季度結束時擁有現金及現金等價物2000萬美金。該公司正在推進其神經退行性疾病項目，使用bezisterim(NE3107)，已完成針對帕金森病的第二階段研究，並設計了一項新的第二階段研究作爲潛在的一線治療。此外，BioVie獲得了1310萬美金的國防部補助，用於評估bezisterim對長期COVID的治療，預計在2025年初開始進行試驗。針對其肝病項目BIV201，BioVie正在根據FDA指導最終確定治療因慢性肝硬化引起的腹水的第三階段研究方案。公司通過多次融資增強了財務狀況，在2024年10月通過註冊直接發行普通股和Warrants籌集了約1590萬美金的總收入。
BioVie報告截至2024年9月30日的2025財年第一季度淨虧損420萬美金，顯著低於去年同期的1070萬美金虧損。研發費用減少了690萬美金，降至200萬美金，主要是由於在前一個財年完成了臨牀試驗。公司在季度結束時擁有現金及現金等價物2000萬美金。該公司正在推進其神經退行性疾病項目，使用bezisterim(NE3107)，已完成針對帕金森病的第二階段研究，並設計了一項新的第二階段研究作爲潛在的一線治療。此外，BioVie獲得了1310萬美金的國防部補助，用於評估bezisterim對長期COVID的治療，預計在2025年初開始進行試驗。針對其肝病項目BIV201，BioVie正在根據FDA指導最終確定治療因慢性肝硬化引起的腹水的第三階段研究方案。公司通過多次融資增強了財務狀況，在2024年10月通過註冊直接發行普通股和Warrants籌集了約1590萬美金的總收入。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    2seventy bio
    TSVT
    -- 4.950
    Syros Pharmaceuticals
    SYRS
    -- 0.1360
    Dogwood Therapeutics
    DWTX
    -- 11.130
    Camp4 Therapeutics
    CAMP
    -- 5.490
    Anebulo Pharmaceuticals
    ANEB
    -- 1.390
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    兩會召開：中概股走勢將如何演變？
    🎙️討論 1. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 2. 你預計“兩會”期間出臺的政策將如何影響你的投資策略？ 3. 你對“兩會”期間股市的波動性有何預期？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點